The American Journal of Digestive Diseases

, Volume 22, Issue 1, pp 43–48 | Cite as

Chronic active hepatitis

Prolonged survival without treatment
  • Timothy O. Lipman
  • Leonard B. Seeff
  • William O. DobbinsIII
Case Report

Summary

A case is presented of a patient with established HBsAg-positive chronic active hepatitis and cirrhosis of at least 14 years duration. The disease, although untreated, has caused the patient relatively little disability. The implications of the patient's prolonged illness are discussed with reference to current knowledge of chronic active hepatitis. It is concluded that corticosteroid therapy may not be a mandatory requirement for all patients with this disease.

Keywords

Public Health Hepatitis Corticosteroid Current Knowledge Corticosteroid Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mistilis SP, Blackburn CRB: Active chronic hepatitis. Am J Med 48:484–495, 1970Google Scholar
  2. 2.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ: Clinical, biochemical and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63:820–833, 1972Google Scholar
  3. 3.
    Cook CG, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40:159–185, 1971Google Scholar
  4. 4.
    Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1:735–737, 1973Google Scholar
  5. 5.
    Henley KS, Appleman HD: The fading menace of chronic hepatitis. Ann Intern Med 82:840–841, 1975Google Scholar
  6. 6.
    Read AE, Sherlock S, Harrison CV: Active “juvenile” cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. Gut 4:378–393, 1963Google Scholar
  7. 7.
    Sherlock S: Progress report: Chronic hepatitis. Gut 15:581–597, 1974Google Scholar
  8. 8.
    Summerskill WHJ, Soloway RD, Baggenstoss AH, Schoenfield LJ: The variety and interrelationship of chronic post-hepatic liver disease with Australia antiginemia (Aug1). Gastroenterology 60:755, 1971 (abstract)Google Scholar
  9. 9.
    Shikata T, Uzawa T, Yoshiwara N, Akaisuka T, Yamazaki S: Staining methods of Australia antigen in paraffin section—detection of cytoplasmic inclusion bodies. Jpn J Med 44(1):25–36, 1974Google Scholar
  10. 10.
    De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uehlinger E, and Wepler W: A classification of chronic hepatitis. Lancet 2:626–628, 1968Google Scholar
  11. 11.
    Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y, Mayumi M: e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 294:746–749, 1976Google Scholar
  12. 12.
    Fay O, Edwards VM, Mosley JW, Redeker AG: The e antigen as an index of chronic hepatitis B virus infection. Gastroenterology 68:1081, 1975 (abstract)Google Scholar
  13. 13.
    Eleftheriou N, Heathcote J, Thomas HC, Sherlock S: Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet 2:1171–1173, 1975Google Scholar
  14. 14.
    Wright R, McCollum RW, Klatskin G: Australia antigen in acute and chronic liver disease. Lancet 2:117–121, 1969Google Scholar
  15. 15.
    Reynolds TB, Peters RL, Yamada S: Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. N Engl J Med 285:813–820, 1971Google Scholar
  16. 16.
    Maddrey WC, Boitnott JK: Isoniazid hepatitis. Ann Intern Med 79:1–12, 1973Google Scholar
  17. 17.
    Rehman OU, Keith TA, Gall EA: Methyldopa-induced submassive hepatic necrosis. JAMA 224:1390–1392, 1973Google Scholar
  18. 18.
    Sternlieb I, Scheinberg IH: Chronic hepatitis as a first manifestation of Wilson's disease. Ann Intern Med 76:59–64, 1972Google Scholar
  19. 19.
    Ishak KG, Jenis EH, Marshall ML, Bolton BH, Battistone GC: Cirrhosis of the liver associated with α1-antitrypsin deficiency. Arch Pathol 94:445–455, 1972Google Scholar
  20. 20.
    Mackay IR: Etiology of chronic hepatitis. The Liver and Its Diseases. F Schaffner, S Sherlock, CM Leevy, (eds). New York, Intercontinental Medical Book Corporation, 1974, pp 191–198Google Scholar
  21. 21.
    Redeker AG: Chronic hepatitis. Med Clin North Am 59:863–867, 1975Google Scholar
  22. 22.
    Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ: Chronic active liver disease: The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 3:183–198, 1972Google Scholar
  23. 23.
    Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: Dose titration, standard dose, and combination with azathioprine compared. Gut 16:976–883, 1975Google Scholar
  24. 24.
    Soloway RD, Summerskill WHJ: Chronic active liver disease: Classification and treatment. Postgrad Med 53:88–94, 1973Google Scholar
  25. 25.
    Plotz PH: Asymptomatic chronic hepatitis. Gastroenterology 68:1629–1630, 1975Google Scholar

Copyright information

© Digestive Disease Systems, Inc. 1977

Authors and Affiliations

  • Timothy O. Lipman
    • 1
    • 2
    • 3
  • Leonard B. Seeff
    • 1
    • 2
    • 3
  • William O. DobbinsIII
    • 1
    • 2
    • 3
  1. 1.Department of MedicineVeterans Administration HospitalWashington, D.C.
  2. 2.Georgetown University School of MedicineWashington, D.C.
  3. 3.Department of Medicinethe George Washington University School of Medicine and Health SciencesWashington, D.C.

Personalised recommendations